This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock AKER vs. MYMD, NAVB, VNRX, MBIO, TNON, POAI, BGLC, MSPR, TSBX, and SSKNShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), VolitionRx (VNRX), Mustang Bio (MBIO), Tenon Medical (TNON), Predictive Oncology (POAI), BioNexus Gene Lab (BGLC), MSP Recovery (MSPR), Turnstone Biologics (TSBX), and Strata Skin Sciences (SSKN). These companies are all part of the "medical" sector. Akers Biosciences vs. Its Competitors MyMD Pharmaceuticals Navidea Biopharmaceuticals VolitionRx Mustang Bio Tenon Medical Predictive Oncology BioNexus Gene Lab MSP Recovery Turnstone Biologics Strata Skin Sciences MyMD Pharmaceuticals (NASDAQ:MYMD) and Akers Biosciences (NASDAQ:AKER) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Do institutionals & insiders hold more shares of MYMD or AKER? 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 5.5% of Akers Biosciences shares are held by institutional investors. 2.1% of MyMD Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Akers Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor MYMD or AKER? In the previous week, MyMD Pharmaceuticals' average media sentiment score of 0.00 equaled Akers Biosciences'average media sentiment score. Company Overall Sentiment MyMD Pharmaceuticals Neutral Akers Biosciences Neutral Is MYMD or AKER more profitable? Akers Biosciences' return on equity of -87.42% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MyMD PharmaceuticalsN/A -179.05% -108.14% Akers Biosciences N/A -87.42%-73.31% Which has more risk & volatility, MYMD or AKER? MyMD Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Akers Biosciences has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Which has higher valuation and earnings, MYMD or AKER? Akers Biosciences has higher revenue and earnings than MyMD Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyMD PharmaceuticalsN/AN/A-$4MN/AN/AAkers Biosciences$1.58M1.04-$3.89MN/AN/A SummaryAkers Biosciences beats MyMD Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.64M$16.73M$5.46B$9.64BDividend YieldN/AN/A3.99%4.14%P/E RatioN/AN/A30.0125.17Price / Sales1.0418.73372.2177.01Price / CashN/AN/A35.9458.58Price / Book0.020.018.155.69Net Income-$3.89M-$15.34M$3.26B$265.48M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$0.10-5.8%N/A-94.3%$1.64M$1.58M0.004Gap DownHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.12-11.5%N/A-94.1%$277KN/A0.006Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010VNRXVolitionRx2.5573 of 5 stars$0.71-3.1%$3.50+394.7%+17.1%$73.57M$1.31M-1.9780News CoverageGap DownMBIOMustang Bio0.1184 of 5 stars$1.63-14.2%N/A-90.1%$8.32MN/A-0.02100Positive NewsUpcoming EarningsGap DownTNONTenon Medical2.5824 of 5 stars$1.05-3.7%$4.67+344.4%+146.8%$8.27M$3.28M-0.048News CoverageUpcoming EarningsPOAIPredictive Oncology1.4541 of 5 stars$0.80+0.0%$3.00+275.0%-19.8%$8.18M$1.62M-0.2630Positive NewsUpcoming EarningsShort Interest ↑BGLCBioNexus Gene Lab0.1803 of 5 stars$4.46-2.0%N/A+29.8%$8.17M$9.51M0.0030Upcoming EarningsMSPRMSP RecoveryN/A$0.95-4.0%N/AN/A$8.16M$18.25M-0.013News CoveragePositive NewsTSBXTurnstone Biologics1.4369 of 5 stars$0.35+0.6%$0.45+26.9%-83.8%$8.16MN/A-0.1382Upcoming EarningsSSKNStrata Skin Sciences2.2584 of 5 stars$1.89-2.1%$6.00+217.5%-37.9%$8.05M$33.62M-0.83120News CoveragePositive NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies MyMD Pharmaceuticals Alternatives Navidea Biopharmaceuticals Alternatives VolitionRx Alternatives Mustang Bio Alternatives Tenon Medical Alternatives Predictive Oncology Alternatives BioNexus Gene Lab Alternatives MSP Recovery Alternatives Turnstone Biologics Alternatives Strata Skin Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKER) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
